Cellectar Biosciences (CLRB) News Today $0.26 +0.01 (+3.33%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Roth Capital Brokers Increase Earnings Estimates for CLRBMay 17, 2025 | americanbankingnews.comCellectar Biosciences (NASDAQ:CLRB) Receives Hold Rating from Maxim GroupMay 16, 2025 | americanbankingnews.comMaxim Group Downgrades Cellectar Biosciences (CLRB)May 15, 2025 | msn.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comCellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2025 | finance.yahoo.comCellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comCellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | globenewswire.comCellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.comMay 13, 2025 | americanbankingnews.comInsights Ahead: Cellectar Biosciences's Quarterly EarningsMay 12, 2025 | benzinga.comCellectar Biosciences (CLRB) Expected to Announce Earnings on TuesdayMay 11, 2025 | americanbankingnews.comCellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025May 7, 2025 | globenewswire.comCellectar explores strategic options to enhance shareholder valueMay 3, 2025 | uk.investing.comCellectar Announces Plan to Explore Strategic AlternativesApril 30, 2025 | globenewswire.comCellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | seekingalpha.comOppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)March 14, 2025 | markets.businessinsider.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | insidermonkey.comQ4 2024 Cellectar Biosciences Inc Earnings CallMarch 14, 2025 | uk.finance.yahoo.comCellectar Biosciences reports FY24 EPS ($1.40), consensus ($1.57)March 13, 2025 | markets.businessinsider.comCellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate UpdateMarch 13, 2025 | globenewswire.comCellectar Biosciences to Present at the 37th Annual Roth ConferenceMarch 11, 2025 | markets.businessinsider.comCellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025March 5, 2025 | globenewswire.comCellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comCellectar faces Nasdaq delisting over share price ruleFebruary 3, 2025 | msn.comCellectar Biosciences files to sell 19.22M shares of common stock for holdersJanuary 30, 2025 | markets.businessinsider.comCellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare ConferenceJanuary 13, 2025 | finance.yahoo.comCellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare ConferenceJanuary 12, 2025 | globenewswire.comCellectar Biosciences downgraded to Perform from Outperform at OppenheimerDecember 12, 2024 | markets.businessinsider.comOppenheimer Downgrades Cellectar Biosciences (CLRB)December 12, 2024 | msn.comCellectar Biosciences trading resumesDecember 11, 2024 | markets.businessinsider.comCellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce CutDecember 11, 2024 | marketwatch.comCellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic OptionsDecember 11, 2024 | benzinga.comCellectar Biosciences trading halted, news pendingDecember 11, 2024 | markets.businessinsider.comCellectar stock plunges 50% post-market on restructuring newsDecember 11, 2024 | seekingalpha.comCellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate RestructuringDecember 10, 2024 | globenewswire.comCellectar Biosciences transferred with Buy rating at LadenburgDecember 6, 2024 | markets.businessinsider.comOppenheimer cuts Cellectar Biosciences stock target, outperform on Q3 financialsNovember 21, 2024 | uk.investing.comPositive Buy Rating on Cellectar Biosciences Driven by Promising Iopofosine-131 Results and Strategic AdvancementsNovember 21, 2024 | markets.businessinsider.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call TranscriptNovember 21, 2024 | msn.comRoth Capital Brokers Decrease Earnings Estimates for CLRBCellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Equities researchers at Roth Capital dropped their FY2024 EPS estimates for Cellectar Biosciences in a note issued to investors on Monday, November 18th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will pNovember 21, 2024 | marketbeat.comCellectar Biosciences price target lowered to $12 from $14 at OppenheimerNovember 20, 2024 | markets.businessinsider.comQ1 Earnings Estimate for CLRB Issued By Roth CapitalCellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Investment analysts at Roth Capital issued their Q1 2025 earnings per share estimates for shares of Cellectar Biosciences in a research note issued on Monday, November 18th. Roth Capital analyst J. Aschoff expects that the biopharmaceuticaNovember 20, 2024 | marketbeat.comOppenheimer Has Lowered Expectations for Cellectar Biosciences (NASDAQ:CLRB) Stock PriceOppenheimer lowered their price target on Cellectar Biosciences from $14.00 to $12.00 and set an "outperform" rating on the stock in a research note on Tuesday.November 19, 2024 | marketbeat.comCellectar Biosciences Reports Q3 2024 Financial ResultsNovember 19, 2024 | markets.businessinsider.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest UpdateCellectar Biosciences, Inc. (NASDAQ:CLRB - Get Free Report) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 1,840,000 shares, a drop of 6.1% from the October 15th total of 1,960,000 shares. Approximately 4.7% of the company's shares are short sold. Based on an average daily volume of 245,400 shares, the days-to-cover ratio is presently 7.5 days.November 18, 2024 | marketbeat.comCellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate UpdateNovember 18, 2024 | globenewswire.comCellectar Biosciences signs strategic supply agreement with NorthStarNovember 14, 2024 | markets.businessinsider.comCellectar Biosciences, Inc.: Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225November 14, 2024 | finanznachrichten.deCellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225November 14, 2024 | globenewswire.comCellectar Biosciences (CLRB) to Release Earnings on MondayCellectar Biosciences (NASDAQ:CLRB) will be releasing earnings before the market opens on Monday, November 18, Zacks reports.November 12, 2024 | marketbeat.comCellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of CancerNovember 12, 2024 | globenewswire.com Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address CLRB Media Mentions By Week CLRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLRB News Sentiment▼0.690.65▲Average Medical News Sentiment CLRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLRB Articles This Week▼111▲CLRB Articles Average Week Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADVM News IRD News XLO News PMVP News RNXT News KPTI News ANEB News CNTB News AVTX News TNYA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLRB) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
